Nanogen to develop molecular diagnostic test for AI
Nanogen, developer of in vitro diagnostic products, has been awarded a $10.4
mln, 2-year contract from the US Centers for Disease Control and Prevention
(CDC) to develop a multi-analyte molecular diagnostic assay for influenza.
With this new contract, Nanogen will develop a fast molecular test that
simultaneously detects and differentiates Influenza Type A, Influenza Type B,
seasonal flu (H1N1 and H3N2) strains, and Respiratory Syncytial Virus (RSV). The
contract provides for a secondary, â€œreflexâ€, test for avian flu strains (H5N1,
H7N1, and H9N1) to be available for samples that are determined to be positive
for Flu A but negative for seasonal flu.
The molecular diagnostic test will be developed in partnership with the
Medical College of Wisconsin (MCW) and HandyLab Inc. According to the company,
it will be significantly more sensitive than current rapid flu tests and is
expected to be conducted in less than half the time.
To comment, register here
Or register to be able to comment.